QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=334BF4959346DFAAAC6638C54DCCCC93;jsessionid=F66F47001557A0E969FED97CF34A09D4;jsessionid=14B2AB536CC7C8C7F2095E8DC9AF3E96;jsessionid=8A9634C6CE363B8C0AE8D841CD9E3926;jsessionid=0B2EBE6AF2BF29719D94E6C5B5A3237C;jsessionid=9B4FC0F5914AEEB35E1E601FD745D642;jsessionid=7584CE2A260E9219F0C8E71C77BBB381 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=334BF4959346DFAAAC6638C54DCCCC93;jsessionid=F66F47001557A0E969FED97CF34A09D4;jsessionid=14B2AB536CC7C8C7F2095E8DC9AF3E96;jsessionid=8A9634C6CE363B8C0AE8D841CD9E3926;jsessionid=0B2EBE6AF2BF29719D94E6C5B5A3237C;jsessionid=9B4FC0F5914AEEB35E1E601FD745D642;jsessionid=7584CE2A260E9219F0C8E71C77BBB381